Place it in its market
Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.
See how Context works →On the price, the facts of the public record◆Adverse 8-K filing◇Significant stake declared (13D)●Results filed
With an account, also○dividends▲splits◌next earningswith an account
End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.
Latest on record
The most recent facts, as filed.
Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.
- Oct 9, 2026Quarterly report · 10-QFiled by the company itself.Open the filing ↗
- Sep 14, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
- Jul 15, 2026Quarterly report · 10-QFiled by the company itself.Open the filing ↗
In numbers
What this profile holds, counted.
Closes · 1 year250
SEC filings on record8069 flagged findings
Reported transactions (Form 4)—not covered
Corporate events (8-K)4since Oct 23, 2025
What the record says
Description, identity and filings, each with its source.
Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.
Regulatory history
Topics detected in its SEC reports, with the original excerpt.
Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.
- 2026-07-15listing compliance noticerecentOpen filing ↗“…below, there have been no material changes to the risk factors previously disclosed under the caption “Risk Factors” in our Annual…”
+1 more passage from the same document
- “…We cannot assure you that we will continue to be listed on the NYSE American. Our common stock currently trades on the NYSE…”
- 2026-07-15capital return (buybacks/dividends)recentOpen filing ↗“…Company does not include an estimate of legal fees and other related defense costs in its estimate of loss contingencies. See “Note…”
+1 more passage from the same document
- “…and Exchange Commission or in such other manner as will comply with the provisions of the Securities Exchange Act of 1934. As of…”
- 2026-05-08listing compliance noticerecentOpen filing ↗“…the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate…”
+1 more passage from the same document
- “…of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has…”
- 2026-04-14listing compliance noticerecentOpen filing ↗“…below, there have been no material changes to the risk factors previously disclosed under the caption “Risk Factors” in our Annual…”
+1 more passage from the same document
- “…We cannot assure you that we will continue to be listed on the NYSE American. Our common stock currently trades on the NYSE…”
- 2026-04-14capital return (buybacks/dividends)recentOpen filing ↗“…Company does not include an estimate of legal fees and other related defense costs in its estimate of loss contingencies. See “Note…”
+1 more passage from the same document
- “…and Exchange Commission or in such other manner as will comply with the provisions of the Securities Exchange Act of 1934. As of…”
- 2026-03-12listing compliance noticerecentOpen filing ↗“…the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate…”
+1 more passage from the same document
- “…of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has…”
Original excerpts from SEC filings, untranslated. Not advice and not a prediction.
Listing notice in force
The exchange has notified the company that it fails a continued-listing requirement (8-K, item 3.01 of May 8, 2026).
- unspecified type · NYSE American, rule Section 1003 · notice of Mar 9, 2026 · plan accepted · deadline not determined
The 25 most recent filings (of 806)
Every SEC filing, newest first, with what it is. Below, each type with its own explanation.
- Oct 13, 26DEF 14A ↗Shareholder meeting and votes new
- Oct 9, 2610-Q ↗Quarterly report
- Sep 14, 268-K ↗Current report · Other events
- Aug 7, 26Form 4 ↗Insider transaction
- Jul 15, 2610-Q ↗Quarterly report
- Jul 7, 26SCHEDULE 13D/A ↗Stake with intent to influence · Camac Partners, LLC · 6.8% · event on Jul 2, 26 · amendment
- May 29, 26Form 4 ↗Insider transaction
- May 8, 268-K ↗Current report · Listing notice (8-K 3.01)
- Apr 14, 2610-Q ↗Quarterly report
- Mar 25, 26SCHEDULE 13D ↗Stake with intent to influence · Camac Partners, LLC · 5.3% · event on Mar 23, 26
- Mar 12, 268-K ↗Current report · Listing notice (8-K 3.01)
- Feb 27, 2610-K ↗Annual report
Insider transaction · 7 Form 4 filingsshow all 7hide
- Nov 12, 258-K ↗Current report · Other events
- Oct 23, 258-K ↗Current report · Entered a material agreement
- Oct 15, 2510-Q ↗Quarterly report
806 filings on record, the oldest from Feb 28, 97.
Listing the 25 most recent filings of the 806 on record.
22
- May 8, 26Listing notice (8-K 3.01)+2 more in the same filing8-K 3.01 ↗
- Mar 12, 26Listing notice (8-K 3.01)+2 more in the same filing8-K 3.01 ↗
- Oct 23, 25Entered a material agreement+2 more in the same filing8-K 1.01 ↗
Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.
Schedule 13D: stake and stated purpose
Filed by holders above 5% of a share class who cannot use the short form. It includes the investor's stated purpose: read it before assuming they seek influence.
- Camac Partners, LLC6.8%Jul 2, 26SCHEDULE 13D/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.
Its sector and its market
Cryo-Cell International, Inc. among Health Care companies
The profile shows what is on record. Context and Radar place the company among those of its sector and region.
Browse its neighbours
Other Health Care companies
- Creative Medical Technology Holdings Inc. CELZ
- Crescent Biopharma, Inc. CBIO
- Crispr Therapeutics AG CRSP
- Cronos Group Inc. CRON
- Crossject S.A. ALCJ
- Cue Biopharma, Inc. CUE
- Cullinan Therapeutics, Inc. CGEM
- Cumberland Pharmaceuticals Inc. CPIX
- Cuprina Holdings (Cayman) Limited CUPR
- Curanex Pharmaceuticals Inc. CURX
With an account you also get
- The four engines — growth, trend, risk and context — each with its word and its score.
- The risk band and the sector phase.
- The company's fundamentals and accounts.
- Watchlist: your list of companies, with the «since you follow it» figure.
The research continues
The profile tells the story. The market sets the scene.
From Cryo-Cell International, Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.
See what deserves a closer look
Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.
See how Radar works →Keep the why
Follow Cryo-Cell International, Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.
See an example review →
Coverage
What sits behind this page.
Where each figure comes from and how far it reaches.
- Prices
- End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
- Series quality
- 250 clean closes in the period.
- SEC records
- 806 documents on file, from Feb 28, 1997 to Oct 13, 2026.
- Company description
- No description available.
- This page
- Generated on Oct 19, 2026; refreshed through the day.
Start at your own pace
Explore first. Go deeper with access.
Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.
Compare plans →- No account
This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.
- Pro
What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.
- Pro+
Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.
Are the prices real time?
No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.
Which SEC documents appear here?
Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.
Why does a European company show no SEC records?
It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.
Before forming a view on a company,
read what is on record.
One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.